Cell line · CVCL_3768
Papers54
1 to 20 of 54
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mortalin and PINK1/Parkin-Mediated Mitophagy Represent Ovarian Cancer-Selective Targets for Drug Development. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The domesticated transposon protein L1TD1 associates with its ancestor L1 ORF1p to promote LINE-1 retrotransposition. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. | NPJ Precis Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background. | J Ovarian Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Chemotherapy Enriches for Proinflammatory Macrophage Phenotypes that Support Cancer Stem-Like Cells and Disease Progression in Ovarian Cancer. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. | Nat Commun | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3768/papers